Hormonal contraceptive continuation and switching in South Africa: Implications for evaluating the association of injectable hormonal contraceptive use and HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 363-365

  Smit, Jennifer A ^a   Beksinska, Mags E ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Combined oral contraceptives; Depot medroxyprogesterone; HIV; Hormonal contraception; Norethisterone enanthate

Indexed keywords

MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; SOUTH AFRICA;

EID: 85027943542     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827e818a     Document Type: Article

References (20)

1. National Department of Health. Medical research Council, OrcMacro. South Africa Demographic and Health Survey 2003. Pretoria, South Africa: National Department of Health; 2007.
2. Beksinska ME, Rees HV, Smit J. Temporary discontinuation: a compliance issue in injectable users. Contraception 2001;64:309-313.
3. National Department of Health. Medical Research Council and Measure DHS+. South Africa Demographic and Health Survey 1998, Full Report. Pretoria, South Africa: National Department of Health; 2002.
4. Beksinska ME, Rees H, Nkonyane T, et al. Compliance and use behaviour, an issue in injectable as well as oral contraceptive use? A study of injectable and oral contraceptive users in Johannesburg. Br J Fam Plann. 1998;24:15-18.
5. Beksinska ME, Kleinschmidt I, Smit JA, et al. Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception. Contraception. 2009;80:128-132.
6. Ali MM, Cleland J. Contraceptive switching after method-related discontinuation: levels and differentials. Stud Fam Plann. 2010;41:129-133.
7. Barden-O'Fallon J, Speizer I. What differentiates method stoppers from switchers? Contraceptive discontinuation and switching among Honduran women. Int Perspect Sex Reprod Health. 2011;37:16-23.
8. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117:1105-1113.
9. Raine TR, Foster-Rosales A, Upadhyay UD, et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol. 2011;117:363-371.
10. Morrison CS, Chen P, Kwok C, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modelling. AIDS. 2010; 24:1778-1781.
11. Baeten JM, Benki S, Chohan V, et al. Hormonal contraceptive use, herpes simplex virus infection, and the risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21:1771-1777.
12. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
13. Morrison CS, Skoler-Karpoff S, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26:497-504.
14. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75:461-467.
15. World Health Organization. Department of Reproductive Health and Research. Hormonal Contraception and HIV, Technical Statement. Geneva, Switzerland: World Health Organization; 2012.
16. World Health Organization. Department of Reproductive Health and Research. The Medical Eligibility Criteria for Contraceptive Use, Fourth Edition. Geneva, Switzerland: World Health Organization; 2009.
17. World Health Organization. Department of Reproductive Health and Research. Programmatic and Research Considerations for Hormonal Contraception for Women at Risk of HIV and Women Living with HIV, Policy Implications. Geneva, Switzerland: World Health Organization; 2012.
18. Beksinska ME, Kleinschmidt I, Smit JA, et al. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depotmedroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception. 2009;79:345-349.
19. Beksinska ME, Smit J, Kleinschmidt I. HIV-1 transmission risks from norethisterone enanthate and depot-medroxyprogesterone acetate should be evaluated separately. Lancet Infect Dis. 2012;12:509.
20. Hapgood JP, Koubovec D, Louw A, et al. Not all progestins are the same: implications for usage. Trends Pharmacol Sci. 2004;11:554-557.